2m 2m 2m 2m 2m 2m 2m
Vertex Pharma (VRTX)
NASDAQ
$468.51+$1.72 (+0.37%)
Price as of Jun 23, 2026 5:00 PM EDT- $118.5BMarket Cap
- 5.24%1-Year Change
- BiotechnologyIndustry
Vertex Pharma (VRTX)
$468.51+$1.72 (+0.37%)
Top Holders
Institutional
Mutual Funds
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
CAPITAL WORLD INVESTORS | 10.00% | 25.4M | -142,058 (-0.56%) | Mar 31, 2026 |
VANGUARD GROUP INC | 9.50% | 24.1M | -111,042 (-0.46%) | Dec 31, 2025 |
BLACKROCK, INC. | 9.44% | 24.0M | +217,528 (+0.91%) | Mar 31, 2026 |
BLACKROCK FUNDING, INC. /DE | 8.60% | 21.8M | +37,924 (+0.17%) | Dec 31, 2024 |
BLACKROCK INC. | 8.40% | 21.3M | -648,443 (-3.04%) | Jun 30, 2024 |
CAPITAL RESEARCH GLOBAL INVESTORS | 8.32% | 21.1M | +3.8M (+18.03%) | Mar 31, 2026 |
N/A | 6.51% | 16.5M | +16.5M (+100.00%) | Mar 31, 2026 |
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
Advisors' Inner Circle Fund III | 18.10% | 45.9M | 0 (0.00%) | Mar 31, 2026 |
VANGUARD INDEX FUNDS | 6.94% | 17.6M | +140,806 (+0.80%) | Mar 31, 2026 |
GROWTH FUND OF AMERICA | 5.42% | 13.8M | +784,365 (+5.70%) | Feb 28, 2026 |
iSHARES TRUST | 2.82% | 7.2M | -375,852 (-5.25%) | Mar 31, 2026 |
INVESTMENT CO OF AMERICA | 2.47% | 6.3M | +832,140 (+13.27%) | Mar 31, 2026 |
AMERICAN BALANCED FUND | 2.34% | 5.9M | +1.3M (+22.10%) | Mar 31, 2026 |
INVESCO QQQ TRUST, SERIES 1 | 2.11% | 5.4M | -341,294 (-6.38%) | Mar 31, 2026 |
Current Ownership Distribution
- Institutions4.2B (72.42%)
- Mutual Funds1.6B (27.53%)
- Insiders3.1M (0.05%)
- Other0 (0.00%)
Insider Transactions
- 0.05% (3.1M)Current InsiderOwnership (%, shares)
- 2Number of InsiderBuying (last 12 months)
- $116.0MAmount of InsiderBuying (last 12 months)
- 13Number of InsiderSelling (last 12 months)
- $1.5BAmount of InsiderSelling (last 12 months)
Insider Name & Title | Type | Date
| Transaction Value | Shares | Share Price | Shares After Transactions |
|---|---|---|---|---|---|---|
Bozic Carmen EVP and CMO | Sell | Jun 18, 2026 | $471,413.40 | 1,020 | $462.17 | 15,933 |
Bozic Carmen EVP and CMO | Sell | Jun 15, 2026 | $1.8M | 4,062 | $450.00 | 16,953 |
Liu Joy EVP and Chief Legal Officer | Sell | Apr 01, 2026 | $439,288.26 | 978 | $449.17 | 21,833 |
Bozic Carmen EVP and CMO | Sell | Mar 27, 2026 | $1.1M | 2,329 | $450.95 | 33,076 |
Bozic Carmen EVP and CMO | Sell | Mar 13, 2026 | $1.1M | 2,329 | $481.79 | 35,405 |
McKechnie Duncan EVP, Chief Commercial Officer | Sell | Mar 11, 2026 | $1.3M | 2,633 | $498.42 | 12,489 |
McKechnie Duncan EVP, Chief Commercial Officer | Sell | Mar 04, 2026 | $1.2M | 2,437 | $475.30 | 15,122 |
Liu Joy EVP and Chief Legal Officer | Sell | Mar 02, 2026 | $442,396.32 | 892 | $495.96 | 22,811 |
Bozic Carmen EVP and CMO | Sell | Feb 27, 2026 | $1.1M | 2,329 | $480.31 | 37,734 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $191,900.00 | 400 | $479.75 | 137,878 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $57,780.00 | 120 | $481.50 | 137,758 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $115,881.60 | 240 | $482.84 | 137,518 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $1.2M | 2,510 | $487.13 | 135,008 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $1.6M | 3,278 | $488.27 | 131,730 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $225,087.20 | 460 | $489.32 | 131,270 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $1.3M | 2,725 | $490.54 | 128,545 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $466,243.70 | 949 | $491.30 | 127,596 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $1.2M | 2,520 | $493.29 | 125,076 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $1.7M | 3,498 | $494.33 | 121,578 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $7.7M | 15,580 | $495.38 | 105,998 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $3.0M | 5,995 | $496.16 | 100,003 |
Kewalramani Reshma CEO & President | Sell | Feb 27, 2026 | $857,238.75 | 1,725 | $496.95 | 98,278 |
Ambrose Kristen SVP & Chief Accounting Officer | Sell | Feb 26, 2026 | $172,559.52 | 357 | $483.36 | 6,624 |
McKechnie Duncan EVP, Chief Commercial Officer | Sell | Feb 25, 2026 | $1.2M | 2,500 | $486.35 | 19,969 |
Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sell | Feb 25, 2026 | $324,881.80 | 668 | $486.35 | 18,432 |
Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sell | Feb 25, 2026 | $126,451.00 | 260 | $486.35 | 46,763 |
Bunnage Mark E. EVP, Chief Scientific Officer | Sell | Feb 25, 2026 | $301,537.00 | 620 | $486.35 | 7,284 |
Sachdev Amit EVP Chief Patient & Ext Af Off | Sell | Feb 25, 2026 | $897,802.10 | 1,846 | $486.35 | 55,570 |
McKechnie Duncan EVP, Chief Commercial Officer | Sell | Feb 25, 2026 | $1.2M | 2,410 | $489.00 | 17,559 |
Ambrose Kristen SVP & Chief Accounting Officer | Sell | Feb 25, 2026 | $108,456.05 | 223 | $486.35 | 6,981 |